CJEM電JCMU

Canadian Journal of Emergency Medicine/Journal canadien de la médicine d'urgence

Volume 20 Issue 6

November 2018/novembre 2018



Inspiring excellence in emergency medical care





Canadian Journal of Emergency Medicine Editorial Board

Editor-in-Chief

Ian G. Stiell, MD, MSc University of Ottawa, Canada

Deputy Editors

Paul Atkinson, MB, BCh, BAO, MA Dalhousie University, Canada

Eddy Lang, MD, CM University of Calgary, Canada

Managing Editor

Jennifer Brinkhurst, BAH Ottawa, Canada

Assistant Managing Editor

Jacqueline Fraser, RNBN Saint John, Canada

Editor Emeritus

James Ducharme, MD McMaster University, Canada

Grant Innes, MD University of Calgary, Canada

Decision Editors

David Barbic, MD, MSc University of British Columbia, Canada

Peter Alistair Cameron, MBBS, MD The Alfred Hospital and Monash University, Australia

Alix Carter, MD, MPH Dalhousie University, Canada

Teresa Chan, MD McMaster University, Canada

Kerstin de Wit, MBChB, BSc, MSc, MD *McMaster University, Canada*

Quynh Doan, MDCM, MHSc, PhD University of British Columbia, Canada

Jeffrey Freeman, MD University of British Columbia, Canada

Ran Goldman, MD, BSc University of Toronto, Canada

Sophie Gosselin, MD McGill University, Canada

Robert S. Green, MD Dalhousie University, Canada

Kirk Magee, MD, MSc Dalhousie University, Canada

Andrew McRae, MD, PhD University of Calgary, Canada

Shawn Mondoux, BEng, MSc, MD McMaster University, Canada

Catherine Patocka, MDCM, MHPE University of Calgary, Canada

Brian Steinhart, MD University of Toronto, Canada

Daniel K. Ting, MD

University of British Columbia - Interior Site, Canada

Peter J. Zed, BSc, PharmD University of British Columbia, Canada

Associate Editors

Garth Dickinson, MD University of Ottawa, Canada

Marcel Émond, MD, MSc Université Laval, Canada

Jeff Eppler, MD

Kelowna General Hospital, University of British Columbia, Canada

Mete Erdogan, BSc, PhD, MHI Dalhousie University, Canada

Devin R. Harris, MD, MHSc University of British Columbia, Canada

Niranjan Kissoon, MD

University of British Columbia, Canada

Patrick McLane, PhD Alberta Health Services, University of Alberta, Canada

Laurie J. Morrison, MD, MSc University of Toronto, Canada

Heather Murray, MD, MSc Queen's University, Canada

Jeffrey Perry, MD, MSc University of Ottawa, Canada

Roy Purssell, MD

University of British Columbia, Canada

Michael J. Schull, MD, MSc University of Toronto, Canada

John M. Tallon, MD, MSc

University of British Columbia, Dalhousie University, Canada

Suneel Upadhye, BS, MD McMaster University, Canada

Social Media Editor

Hans Rosenberg, MD University of Ottawa, Canada



Vol. 20, No. 6 November 2018/ novembre 2018

cjem-online.ca



For *CJEM's* next audio summary describing the best editorials and articles in our November issue, visit https://soundcloud.com/user-124260332/cjem-november-issue-2018-audio-summary. Enjoy the summary and the music!

Table of Contents • Table des matières

CLINICIAN'S CAPSULES

809 Clinician's Capsules for CJEM 20(6)

COMMENTARY

- 811 Delirium in older emergency department patients Debra Eagles
- ST-segment elevation myocardial infarction (STEMI) bypass: The importance of paramedics in an integrated STEMI system of care Alix J. E. Carter
- 816 You don't need a mentor; you need a board of directors Jonathan Sherbino
- FOAMed and social media innovation or disruption? The effect of an infographic promotion on research dissemination and readership:
 A randomized controlled trial. An editorial on Free Open Access Medical education
 Shahbaz Syed, Hans Rosenberg

CJEM Debate Series

#PhysicianProductivity – Measuring and understanding causes of variability in emergency physician performance are essential to improve emergency department efficiency W. Richard Bukata, Heather Murray, Paul Atkinson

FEATURE ARTICLE

826 The effect of an infographic promotion on research dissemination and readership: A randomized controlled trial
Simon Huang, Lynsey J. Martin, Calvin H. Yeh, Alvin Chin,
Heather Murray, William B. Sanderson, Rohit Mohindra,
Teresa M. Chan, Brent Thoma

CARDIOLOGY

834 Rhythm and rate control of atrial fibrillation in the emergency department – A large community-based observational study Cameron J. Gilbert, Paul Angaran, Zana Mariano, Theresa Aves, Paul Dorian





Effects of a reminder to initiate oral anticoagulation in patients with atrial fibrillation/atrial flutter discharged from the emergency department: REMINDER study Saman Rezazadeh, Derek S. Chew, Robert J.H. Miller, Sheila Klassen, Payam Pournazari, Graham Bennett, Eddy Lang, F. Russell Quinn

PREHOSPITAL

- 850 Evaluation of a primary care paramedic STEMI bypass guideline Jonathan Kwong, Garry Ross, Linda Turner, Chris Olynyk, Sheldon Cheskes, Adam Thurston, RN, P. Richard Verbeek
- 857 Clinical adverse events in prehospital patients with ST-elevation myocardial infarction transported to a percutaneous coronary intervention centre by basic life support paramedics in a rural region Sylvain Bussières, François Bégin, Pierre-Alexandre Leblanc, Alain Tanguay, Jean-Michel Paradis, Denise Hébert, Richard Fleet
- Safety and clinically important events in a PCP initiated STEMI bypass in Ottawa Simeon Mitchell, Richard Dionne, Justin Maloney, Mike Austin, Garrick Mok, Julie Sinclair, A-EMCA, Catherine Cox, Michel Le May Christian Vaillancourt
- 874 Correlation of age and rurality with low-urgency use of emergency medical services (LUEMS):
 A geographic analysis
 Mikiko Terashima, Alix J.E. Carter

PEDIATRICS • PÉDIATRIE

- A Web-based module and online video for pain management education for caregivers of children with fractures: A randomized controlled trial Stevi Golden-Plotnik, Samina Ali, Amy L. Drendel, Tammy Wong, Frank Ferlisi, Sydney Todorovich, Kyle Canton, Michael Miller, Julia Younan, Sharlene Elsie, Naveen Poonai
- 892 Is caregiver refusal of analgesics a barrier to pediatric emergency pain management?
 A cross-sectional study in two Canadian centres
 Caroline Whiston, Samina Ali, Bruce Wright, David Wonnacott, Antonia S. Stang,
 Graham C. Thompson, Chirag Bhat, Sydney Todorovich, Ashutosh Mishra, Dora Laczko,
 Michael Miller, Naveen Poonai

GERIATRICS • GÉRIATRIE

- 903 Performance of the French version of the 4AT for screening the elderly for delirium in the emergency department
 - Anne-Julie Gagné, Philippe Voyer, Valérie Boucher, Alexandra Nadeau, Pierre-Hugues Carmichael, Mathieu Pelletier, Emilie Gouin, Simon Berthelot, Raoul Daoust, Machelle Wilchesky, Hélène Richard, Isabelle Pelletier, Stephanie Ballard, Antoine Laguë, Marcel Émond
- 911 Risk factors associated with acute in-hospital delirium for patients diagnosed with a hip fracture in the emergency department Cameron Thompson, Vince J.M. Brienza, Aislinn Sandre, Sean Caine, Bjug Borgundvaag, Shelley McLeod

QUALITY IMPROVEMENT

- 920 Real-time video telemedicine applications in the emergency department: a scoping review of literature
 - Danielle K. Kelton, Adam Szulewski, Daniel Howes
- 929 Emergency department boarding: a descriptive analysis and measurement of impact on outcomes Leila Salehi, Prashant Phalpher, Rahim Valani, Christopher Meaney, Qamar Amin, Kiki Ferarri, Mathew Mercuri

CJEM JOURNAL CLUB

- 938 Are lateral ankle injuries in children fractures or sprains? Erica Beatty, Maude Deschênes, Patrick Archambault
- 941 CT HEAD? Reviewing the newest validation of the Ottawa Subarachnoid Hemorrhage Rule James Powell, Mark Sanderson, Eddy Lang

EDUCATION • ENSEIGNEMENT

- 944 Faculty mentorship during residency and professional development among practising emergency physicians
 Shannon M. Fernando, Warren J. Cheung, Stephen B. Choi, Lisa Thurgur, Jason R. Frank
- 952 Competency in Acute ResuscitationThrough Successive Simulation (CARTSS): a mentor based, near-peer learning initiative

 John R. O'Leary, Natasha L. Goumeniouk, Alexander S. Cormier, Daniel J. Potter, Filip Gilic,

 Erin E. Brennan

HUMANITY • HUMANITÉ

955 Darkness in the North Michelle Yee

CLINICAL CORRESPONDENCE • CORRESPONDANCE CLINIQUE

- 957 Bilateral ureterolithiasis: A true positive and false negative PoCUS exam in a patient with renal colic Matthew P. Lowe, Christopher Cox
- 962 Poisoning from the Kambô ritual Alexander Kumachev, Jonathan S. Zipursky, Adina S. Weinerman, Margaret Thompson

GLOBAL RESEARCH HIGHLIGHTS • FAITS MARQUANTS DE LA RECHERCHE MONDIALE

965 International Abstracts

LETTERS (ONLINE ONLY)

Letter in response to: "CJEM Debate series: #choosingwisely—The choosing wisely campaign will not impact physician behaviour and choices"

Karen Born, Andrea Patey, Jeremy Grimshaw, Wendy Levinson

WWGD (What would Gwyneth do?)

Deepa Soni

Introducing **Penthrox** methoxuflurane

PENTHROX™ (methoxyflurane) is indicated for short-term relief of moderate to severe acute pain, associated with trauma or interventional medical procedures, in conscious adult patients.1

Inhaled PENTHROX™ provides RAPID onset > of analgesic activity

Expected median onset of pain relief is 5 minutes¹

Demonstrated EFFECTIVE reduction in pain intensity score vs. placebo in adults with acute pain associated with trauma

PENTHROX™ significantly reduced mean change in VAS pain intensity score overall from baseline vs. placebo

The estimated mean change overall in VAS pain from baseline was greater with PENTHROX™ -29 mm (n=102) vs. placebo -11.6 mm (n=101) (estimated treatment effect: -17.4 mm; 95% confidence interval [CI]: -22.3 to -12.5 mm; p<0.0001).12*

Demonstrated EFFECTIVE lower worst pain overall during bone marrow biopsy vs. placebo in adults

Mean worst pain overall (the highest of two patient-rated pain scores (NRS) at two time points: pain during aspiration and pain during core biopsy) during bone marrow biopsy procedure was significantly lower for PENTHROX™ vs. placebo (4.9 vs. 6.0; p=0.011)1,31

Mean worst pain score during:1,3

- $^{\circ}$ Aspiration was significantly lower with PENTHROX $^{\text{\tiny{M}}}$ than placebo (3.3 vs. 5.0; p<0.001)
- ° Core biopsy was not statistically significantly different for PENTHROX™ vs. placebo (4.5 vs. 5.4; p=0.073)

SELF-ADMINISTERED under supervision[‡]

PENTHROX™ should be self-administered under the supervision of a healthcare practitioner, trained in its administration, using the hand-held PENTHROX™ Inhaler.

Patients can assess their own level of pain and titrate the amount of PENTHROX™ inhaled for adequate pain control. Continuous inhalation provides analgesic relief for up to 25–30 minutes, or approximately 1 hour when administered

Patients should be instructed to inhale intermittently and to take the lowest possible dose to achieve pain relief.



- * A randomized, double-blind, multi-centre, placebo-controlled study in the treatment of acute pain in patients with minor trauma presenting to an emergency department. A total of 300 patients (203 adults, 95 adolescents; PENTHROX™ is not indicated in adolescents) were recruited (149 received PENTHROX" and 149 received placebo). Patients with a pain score of ≥ 4 to ≤ 7 on the NRS were eligible for the study. One to two PENTHROX" Inhalers containing 3 mL of methoxyflurane or 5 mL of placebo was administered. The duration of the study was 16 days. \(^{12}
- † A phase IV, randomized, double-blind, single-centre, placebo-controlled study to evaluate the efficacy and safety of PENTHROX™ for the treatment of incident pain in adult patients requiring analgesia associated with a planned bone marrow biopsy (BMB) procedure. Forty-nine patients were randomized to PENTTHROX" and 48 patients to placebo.^{1.3} ‡ Please refer to Product Monograph for complete dosing and administration information.

CI=confidence interval; NRS=numeric rating scale; VAS=visual analog score

Clinical Use:

Due to dose limitations of a treatment course of PENTHROX™ and the duration of associated pain relief, PENTHROX $^{\scriptscriptstyle{\text{TM}}}$ is not appropriate for providing relief of break-through pain in chronic pain conditions. PENTHROX™ is also not appropriate for relief of repetitive pain. PENTHROX™ is not indicated for use during pregnancy or the peripartum period, including labour.

Contraindications:

- Altered level of consciousness due to any cause including head injury, drugs, or alcohol
- · Clinically significant renal impairment
- · History of liver dysfunction after previous methoxyflurane use or other halogenated anesthetics
- · Hypersensitivity to methoxyflurane or any other halogenated anesthetics
- Known or genetically susceptible to malignant hyperthermia or a history of severe adverse reactions in either patient or relatives
- · Clinically evident hemodynamic instability
- · Clinically evident respiratory impairment
- · Use as an anesthetic agent

Most Serious Warnings and Precautions:

- Nephrotoxicity: Supratherapeutic doses of methoxyflurane inhalation have been shown to lead to serious, irreversible nephrotoxicity in a dose-related manner. Dosing limitations should be followed meticulously to prevent or limit risk of nephrotoxicity. Consecutive day use of PENTHROX™ is not recommended because of nephrotoxic potential. The lowest effective dose should be administered, especially in the elderly or in patients with other known risk factors of renal disease.
- Hepatotoxicity: Very rare cases of hepatotoxicity have been reported with methoxyflurane inhalation when used for analgesic purposes. Use with care in patients with underlying hepatic conditions or having risk factors for hepatic dysfunction. PENTHROX™ must not be used in patients who have a history of showing signs of liver damage after previous methoxyflurane use or halogenated hydrocarbon anesthesia.

Other Relevant Warnings and Precautions:

- Potential CNS effects
- Administer with caution in elderly patients with hypotension and bradycardia due to possible reduction in blood pressure
- Drug dependence
- May influence the ability to drive and operate machinery
- · Do not administer concomitantly with alcohol ingestion
- To reduce occupational exposure to methoxyflurane, the PENTHROX™ Inhaler should always be used with the activated carbon chamber to adsorb exhaled methoxyflurane
- · Local skin reactions or irritation to the eyes and mucous membranes
- Exercise caution if administering to a nursing mother

Please consult the Product Monograph at http://purdue.ca/en/ <u>products/Penthrox-PM</u> for important information relating to adverse reactions, drug interactions, patient counselling, and dosing/ disposal information (regarding the total maximum dose for a single administration or over the first day of treatment, in a single 48-hour period and entire treatment course) which have not been discussed

The Product Monograph is also available by calling us at 1-800-387-

1. PENTHROX™ Product Monograph. Purdue Pharma. April 6, 2018. 2. Coffey F, et al. Methoxyflurane analgesia in adult patients in the emergency department: A subgroup analysis of a randomized, double-blind, placebo-controlled study (STOP!). Adv Ther. 2016;33(11):2012-2031. 3. Spruyt O, et al. A randomised, double-blind, placebo-controlled study to assess the safety and efficacy of methoxyflurane for procedural pain of a bone marrow biopsy. BMJ Support Palliat Care. 2014;4(4):342-348.

PENTHROX™ is a trademark of Medical Developments International Limited, used under license by Purdue Pharma









